Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on asymmetric hydrogenation. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel phosphoramidite ligands offer high ee values and scalable synthesis for pharmaceutical intermediates manufacturing with significant cost advantages.
Patent CN105001159A enables chiral phosphoric acid catalysis for quinoline-3-amine hydrogenation. Delivers high ee values and scalable pharmaceutical intermediate manufacturing solutions.
Patent CN111484533B discloses novel Ir-SpiroPNP catalysts achieving 99.8% ee in dialkyl ketone hydrogenation, offering cost reduction in pharmaceutical intermediate manufacturing.
Patent CN102532149B details a scalable asymmetric synthesis for Galanthamine. This report analyzes cost reduction in API manufacturing and supply chain reliability for pharmaceutical intermediates.
Patent CN104961640A reveals a cost-effective rhodium-catalyzed synthesis route for high-purity chiral intermediates, ensuring supply chain stability and safety.
This patent details asymmetric hydrogenation for hydantoin derivatives offering high selectivity and atom economy for scalable pharmaceutical intermediate manufacturing supply chains.
Patent CN102984945B details a high-yield asymmetric hydrogenation process for Ramipril and Perindopril intermediates, offering significant cost and purity advantages for pharmaceutical supply chains.
This novel ruthenium catalyst method ensures high dr value and cost reduction in pharmaceutical intermediates manufacturing for reliable supply chain partners globally.
Patent CN110551037B details a high-efficiency iridium/chiral diphosphine system for asymmetric hydrogenation, offering superior enantioselectivity for agrochemical intermediates.
Patent CN112824374B details a nickel-catalyzed asymmetric hydrogenation method for chiral amines, offering cost-effective alternatives to precious metals for pharmaceutical intermediates.
Patent CN112047856B details efficient Rh-catalyzed asymmetric hydrogenation for high-purity chiral alpha-amidoaldehydes, offering significant cost reduction and supply chain stability for pharma manufacturing.
Patent CN102304007B reveals high-ee asymmetric hydrogenation using chiral Ru catalysts enabling cost reduction in pharmaceutical intermediate manufacturing with scalable processes.
Novel iridium catalyst system enables high-yield asymmetric hydrogenation for metolachlor intermediates, offering scalable cost reduction and supply reliability.
Patent CN114539328B reveals surfactant-promoted route enhancing yield and purity. Delivers supply chain stability and cost efficiency for global buyers.
Patent CN111690009A discloses novel Co/Fe complexes for high-ee hydrogenation of alpha-silyl styrenes, offering cost-effective pharma intermediate synthesis.
Patent CN110396072B details a cost-effective dual-catalyst route for (S)-3-hydroxytetrahydrofuran, offering high optical purity and scalable manufacturing for global pharmaceutical supply chains.
Patent CN103193679B enables high ee value asymmetric hydrogenation for Rivastigmine intermediate, ensuring cost reduction and supply reliability.
Patent CN113980017A reveals a high-yield asymmetric hydrogenation route for tetrahydro-13-methyl berberine derivatives, offering significant cost reduction and scalability for pharmaceutical manufacturing.
Patent CN111793017A details a safe ruthenium-catalyzed transfer hydrogenation method for high-ee lactams, offering significant cost and safety advantages for pharmaceutical manufacturing.
Novel phosphite ester patent CN120504699A enables mild asymmetric hydrogenation. Reduces cost and improves supply chain reliability for pharmaceutical intermediates.